Silence Therapeutics Plc (SLNCF)
6.526
+0.17
(+2.70%)
USD |
OTCM |
Nov 12, 16:00
Silence Therapeutics Enterprise Value : 853.12M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 853.12M |
| November 11, 2026 | 828.81M |
| November 10, 2026 | 828.81M |
| November 09, 2026 | 828.81M |
| November 06, 2026 | 828.81M |
| November 05, 2026 | 852.20M |
| November 04, 2026 | 852.20M |
| November 03, 2026 | 852.20M |
| November 02, 2026 | 852.20M |
| October 30, 2026 | 852.20M |
| October 29, 2026 | 830.94M |
| October 28, 2026 | 830.94M |
| October 27, 2026 | 830.94M |
| October 26, 2026 | 830.94M |
| October 23, 2026 | 830.94M |
| October 22, 2026 | 830.94M |
| October 21, 2026 | 830.94M |
| October 20, 2026 | 830.94M |
| October 19, 2026 | 816.05M |
| October 16, 2026 | 473.75M |
| October 15, 2026 | 473.75M |
| October 14, 2026 | 473.75M |
| October 13, 2026 | 473.75M |
| October 12, 2026 | 473.75M |
| October 09, 2026 | 473.75M |
| Date | Value |
|---|---|
| October 08, 2026 | 495.01M |
| October 07, 2026 | 495.01M |
| October 06, 2026 | 495.01M |
| October 05, 2026 | 495.01M |
| October 02, 2026 | 495.01M |
| October 01, 2026 | 495.01M |
| September 30, 2026 | 495.01M |
| September 29, 2026 | 495.01M |
| September 28, 2026 | 495.01M |
| September 25, 2026 | 495.01M |
| September 24, 2026 | 495.01M |
| September 23, 2026 | 495.01M |
| September 22, 2026 | 495.01M |
| September 21, 2026 | 495.01M |
| September 18, 2026 | 495.01M |
| September 17, 2026 | 495.01M |
| September 16, 2026 | 495.01M |
| September 15, 2026 | 495.01M |
| September 14, 2026 | 495.01M |
| September 11, 2026 | 495.01M |
| September 10, 2026 | 495.01M |
| September 09, 2026 | 495.01M |
| September 08, 2026 | 495.01M |
| September 04, 2026 | 495.01M |
| September 03, 2026 | 495.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -20.99M |
| Mereo BioPharma Group Plc | 23.19M |
| Compass Pathways Plc | 902.15M |
| HemoGenyx Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Gross Profit Margin (Quarterly) | 72.27% |
| Profit Margin (Quarterly) | -3.54K% |
| Earnings Yield | -4.22% |
| Normalized Earnings Yield | -6.483 |